

Tricia Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/417938/publications.pdf>

Version: 2024-02-01

130
papers

3,787
citations

136885

32
h-index

149623

56
g-index

140
all docs

140
docs citations

140
times ranked

4973
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between high serum total cortisol concentrations and mortality from COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 659-660.	5.5	193
2	Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. <i>Diabetes</i> , 2013, 62, 1131-1138.	0.3	182
3	Targeting GLP-1 receptor trafficking to improve agonist efficacy. <i>Nature Communications</i> , 2018, 9, 1602.	5.8	162
4	Thyroid Function Before, During, and After COVID-19. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e803-e811.	1.8	143
5	The role of the gut/brain axis in modulating food intake. <i>Neuropharmacology</i> , 2012, 63, 46-56.	2.0	130
6	Ghrelin Can Bind to a Species of High Density Lipoprotein Associated with Paraoxonase. <i>Journal of Biological Chemistry</i> , 2003, 278, 8877-8880.	1.6	123
7	Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake. <i>Diabetes</i> , 2014, 63, 3711-3720.	0.3	119
8	Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 72-81.	2.2	118
9	Somatostatin Infusion Lowers Plasma Ghrelin without Reducing Appetite in Adults with Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4162-4165.	1.8	113
10	Minireview: Glucagon in Stress and Energy Homeostasis. <i>Endocrinology</i> , 2012, 153, 1049-1054.	1.4	111
11	The future role of gut hormones in the treatment of obesity. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 4-14.	1.1	106
12	Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 549-559.	5.5	100
13	A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1266-1270.	3.3	99
14	68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours. <i>Molecular Imaging and Biology</i> , 2011, 13, 769-775.	1.3	90
15	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. <i>Diabetes Care</i> , 2019, 42, 1446-1453.	4.3	84
16	The effects of kisspeptin on β -cell function, serum metabolites and appetite in humans. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2800-2810.	2.2	74
17	The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2364-2372.	1.8	72
18	Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1498-1501.	2.2	61

#	ARTICLE	IF	CITATIONS
19	ORIGINAL ARTICLE: Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. <i>Clinical Endocrinology</i> , 2010, 73, 369-374.	1.2	54
20	Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001858.	1.2	52
21	Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans. <i>Journal of Nuclear Medicine</i> , 2018, 59, 516-522.	2.8	51
22	Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. <i>European Journal of Endocrinology</i> , 2017, 177, 455-464.	1.9	50
23	Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2208-2220.	1.8	50
24	The Obesity Epidemic: Pharmacological Challenges. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2008, 8, 82-98.	3.4	49
25	An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. <i>British Journal of Cancer</i> , 2014, 110, 115-122.	2.9	46
26	Redefining the stress cortisol response to surgery. <i>Clinical Endocrinology</i> , 2017, 87, 451-458.	1.2	46
27	Gut hormones as therapeutic agents in treatment of diabetes and obesity. <i>Current Opinion in Pharmacology</i> , 2013, 13, 996-1001.	1.7	45
28	Peptide receptor radionuclide therapy for metastatic paragangliomas. <i>Medical Oncology</i> , 2016, 33, 47.	1.2	44
29	Genetic and biased agonist-mediated reductions in β -arrestin recruitment prolong cAMP signaling at glucagon family receptors. <i>Journal of Biological Chemistry</i> , 2021, 296, 100133.	1.6	41
30	Immunohistochemical markers of the hypoxic response can identify malignancy in pheochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. <i>British Journal of Cancer</i> , 2013, 108, 429-437.	2.9	40
31	Emerging therapies in the treatment of "diabetes": beyond GLP-1. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 8-15.	4.0	35
32	Oxyntomodulin analogue increases energy expenditure via the glucagon receptor. <i>Peptides</i> , 2018, 104, 70-77.	1.2	35
33	Hormonal interactions between gut and brain. <i>Discovery Medicine</i> , 2010, 10, 543-52.	0.5	35
34	RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling. <i>Endocrinology</i> , 2017, 158, 2680-2693.	1.4	33
35	The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 345-360.	2.5	32
36	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 47.	3.0	32

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 232-239.	1.1	30
38	Gastrointestinal hormones and their role in obesity. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 18-22.	1.2	29
39	Cracking the combination: Gut hormones for the treatment of obesity and diabetes. <i>Journal of Neuroendocrinology</i> , 2019, 31, e12664.	1.2	29
40	Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8404.	1.8	28
41	Combination of Peptide YY ₃₋₃₆ with GLP-1 ₇₋₃₆ amide Causes an Increase in First-Phase Insulin Secretion after IV Glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2317-E2324.	1.8	27
42	Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. <i>Journal of Applied Laboratory Medicine</i> , The, 2016, 1, 152-161.	0.6	27
43	Multicentre study of investigation and management of inpatient hyponatraemia in the UK. <i>Postgraduate Medical Journal</i> , 2014, 90, 694-698.	0.9	25
44	Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling. <i>Molecular Metabolism</i> , 2021, 53, 101296.	3.0	23
45	Limitations of the DiaRem Score in Predicting Remission of Diabetes Following Roux-En-Y Gastric Bypass (RYGB) in an ethnically Diverse Population from a Single Institution in the UK. <i>Obesity Surgery</i> , 2017, 27, 782-786.	1.1	22
46	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. <i>Frontiers in Endocrinology</i> , 2018, 9, 442.	1.5	22
47	A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY ₃₋₃₆ . <i>Endocrinology</i> , 2011, 152, 4630-4640.	1.4	21
48	Gut-brain cross-talk in appetite regulation. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2010, 13, 588-593.	1.3	18
49	Analogues of pancreatic polypeptide and peptide YY with a locked PP-fold structure are biologically active. <i>Peptides</i> , 2013, 39, 6-10.	1.2	18
50	Development of a high-throughput UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma. <i>Bioanalysis</i> , 2014, 6, 3295-3309.	0.6	18
51	Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001076.	1.2	18
52	Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. <i>Journal of Endocrinology</i> , 2020, 246, R65-R74.	1.2	18
53	Gut Hormones and Obesity. <i>Vitamins and Hormones</i> , 2013, 91, 143-194.	0.7	17
54	Beyond Weight Loss: Establishing a Postbariatric Surgery Patient Support Group—What Do Patients Want?. <i>Journal of Obesity</i> , 2018, 2018, 1-7.	1.1	17

#	ARTICLE	IF	CITATIONS
55	Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome. <i>Current Diabetes Reports</i> , 2020, 20, 26.	1.7	17
56	Weight Loss by Low-Calorie Diet Versus Gastric Bypass Surgery in People With Diabetes Results in Divergent Brain Activation Patterns: A Functional MRI Study. <i>Diabetes Care</i> , 2021, 44, 1842-1851.	4.3	17
57	Performance of plasma kisspeptin as a biomarker for miscarriage improves with gestational age during the first trimester. <i>Fertility and Sterility</i> , 2021, 116, 809-819.	0.5	17
58	Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases. <i>Endocrinology</i> , 2017, 158, 1755-1765.	1.4	16
59	The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e767-e782.	1.8	16
60	Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism. <i>Clinical Endocrinology</i> , 2013, 78, 738-742.	1.2	15
61	Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones. <i>Postgraduate Medicine</i> , 2015, 127, 494-502.	0.9	15
62	Comparison of the Utility of Cocaine- and Amphetamine-Regulated Transcript (CART), Chromogranin A, and Chromogranin B in Neuroendocrine Tumor Diagnosis and Assessment of Disease Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1520-1528.	1.8	15
63	Dopamine agonists and hyperprolactinaemia. <i>BMJ: British Medical Journal</i> , 2009, 338, b381-b381.	2.4	15
64	Comparison of Diabetic Ketoacidosis in Adults During the SARS-CoV-2 Outbreak and Over the Same Time Period for the Preceding 3 Years. <i>Diabetes Care</i> , 2021, 44, e29-e31.	4.3	15
65	Adrenal venous sampling as a diagnostic procedure for primary hyperaldosteronism: experience from a tertiary referral centre. <i>Hormones</i> , 2012, 11, 151-159.	0.9	14
66	The Effect of Standard Versus Longer Intestinal Bypass on GLP-1 Regulation and Glucose Metabolism in Patients With Type 2 Diabetes Undergoing Roux-en-Y Gastric Bypass: The Long-Limb Study. <i>Diabetes Care</i> , 2021, 44, 1082-1090.	4.3	14
67	High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy. <i>Clinical Endocrinology</i> , 2009, 70, 812-813.	1.2	13
68	Insulin-mediated "pseudoacromegaly". <i>Hormones</i> , 2011, 10, 156-161.	0.9	13
69	Pituitary macroadenomas: are combination antiplatelet and anticoagulant therapy contraindicated? A case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 74.	0.4	12
70	MELAS syndrome, diabetes and thyroid disease: the role of mitochondrial oxidative stress. <i>Clinical Endocrinology</i> , 2009, 70, 340-341.	1.2	12
71	Metabolic Changes and Diabetes Microvascular Complications 5 Years After Obesity Surgery. <i>Obesity Surgery</i> , 2019, 29, 3907-3911.	1.1	12
72	Development of a UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon and dosed GLP-1 from human plasma. <i>Bioanalysis</i> , 2017, 9, 733-751.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1119-1125.	1.8	11
74	Changes in Circulating Kisspeptin Levels During Each Trimester in Women With Antenatal Complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e71-e83.	1.8	11
75	Inhaled insulin in type 1 diabetes. <i>Lancet</i> , The, 2001, 357, 1979.	6.3	10
76	Vitamin D Status in Patients with Osteopenia or Osteoporosis – an Audit of an Endocrine Clinic. <i>International Journal for Vitamin and Nutrition Research</i> , 2006, 76, 307-313.	0.6	10
77	Candy cane revision after Roux-en-Y gastric bypass. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 2076-2081.	1.3	10
78	Treating the obese diabetic. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 171-183.	1.3	9
79	The preanalytical stability of glucagon as measured by liquid chromatography tandem mass spectrometry and two commercially available immunoassays. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 293-296.	0.8	9
80	Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 1151-1159.	2.5	9
81	Safety and efficacy of an extended-release peptide <sc>YY</sc> analogue for obesity: A randomized, placebo-controlled, phase <sc>1</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1471-1483.	2.2	9
82	Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study. <i>Diabetes Care</i> , 2021, 44, 614-617.	4.3	9
83	Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1529-1540.	1.8	9
84	Can Bayliss and Starling gut hormones cure a worldwide pandemic?. <i>Journal of Physiology</i> , 2014, 592, 5153-5167.	1.3	8
85	The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism. <i>Endocrine Connections</i> , 2021, 10, R66-R76.	0.8	8
86	Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E671-E679.	1.8	8
87	Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. <i>Biochemical Pharmacology</i> , 2021, 190, 114656.	2.0	8
88	Preserved <sc>C</sc>-peptide in survivors of <sc>COVID</sc>-19: Post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 570-574.	2.2	8
89	What Can We Learn From Mouse Models About Bile Acid-Mediated Changes After Bariatric Surgery?. <i>Gastroenterology</i> , 2019, 157, 4-8.	0.6	7
90	Long limb compared with standard limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-54.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. <i>Molecular Metabolism</i> , 2021, 51, 101242.	3.0	7
92	The pursuit of beauty. <i>Lancet, The</i> , 2008, 371, 596.	6.3	6
93	Cortisol concentrations and mortality from COVID-19 – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 809-810.	5.5	6
94	A glucagon analogue decreases body weight in mice via signalling in the liver. <i>Scientific Reports</i> , 2021, 11, 22577.	1.6	6
95	The clinical outcomes, appetite and metabolic effects of sleeve gastrectomy and Roux-en-Y gastric bypass: A comparative review. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, 22, 100315.	0.6	5
96	Identification of plasma protease derived metabolites of glucagon and their formation under typical laboratory sample handling conditions. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 171-181.	0.7	4
97	Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo. <i>Lancet, The</i> , 2015, 385, S28.	6.3	4
98	Of Mice Not Men? Actions of Interleukin-6 on Glucose Tolerance. <i>Cell Metabolism</i> , 2018, 27, 1157-1158.	7.2	4
99	Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 987-989.	0.2	4
100	Tirzepatide and the new era of twincretins for diabetes. <i>Lancet, The</i> , 2021, 398, 95-97.	6.3	4
101	UK recommendations for germline genetic testing and surveillance in clinical practice. <i>Journal of Medical Genetics</i> , 2023, 60, 107-111.	1.5	4
102	The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1385-1389.	2.2	4
103	Hepatocyte cholesterol content modulates glucagon receptor signalling. <i>Molecular Metabolism</i> , 2022, 63, 101530.	3.0	4
104	Learning curve of vessel cannulation in rats using cumulative sum analysis. <i>Journal of Surgical Research</i> , 2015, 193, 69-76.	0.8	3
105	Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 833-838.	1.8	3
106	Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1899-1905.	1.8	3
107	Imperial Satiety Protocol: A new non-surgical weight loss programme, delivered in a health care setting, produces improved clinical outcomes for people with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 270-275.	2.2	3
108	Improving the Interpretation of Afternoon Cortisol Levels and SSTs to Prevent Misdiagnosis of Adrenal Insufficiency. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab147.	0.1	3

#	ARTICLE	IF	CITATIONS
109	Surpassing insulin glargine in type 2 diabetes with tirzepatide. <i>Lancet, The</i> , 2021, 398, 1779-1781.	6.3	3
110	Late-night salivary cortisol and cortisone should be the initial screening test for Cushing's syndrome. <i>Endocrine Connections</i> , 2022, 11, .	0.8	3
111	Familial adenomatous polyposis and hypertension. <i>Lancet, The</i> , 2010, 375, 1752.	6.3	2
112	A man with anxiety, confusion, and red eyes. <i>BMJ, The</i> , 2012, 345, e4443-e4443.	3.0	2
113	Pancreatic Polypeptide. , 2013, , 1294-1299.		2
114	Gut hormones and Type 2 diabetes mellitus. <i>Diabetes Management</i> , 2014, 4, 501-513.	0.5	2
115	Clinical roles in clinical biochemistry: a national survey of practice in the UK. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 370-377.	0.8	2
116	Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 269-270.	5.5	2
117	Synacthen Stimulation Test Following Unilateral Adrenalectomy Needs to Be Interpreted With Caution. <i>Frontiers in Endocrinology</i> , 2021, 12, 654600.	1.5	2
118	¹ H NMR Signals from Urine Excreted Protein Are a Source of Bias in Probabilistic Quotient Normalization. <i>Analytical Chemistry</i> , 2022, 94, 6919-6923.	3.2	2
119	PYY. , 2013, , 1160-1165.		1
120	Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. <i>Journal of Investigative Surgery</i> , 2017, 30, 162-169.	0.6	1
121	Who will benefit from bariatric surgery for diabetes? A protocol for an observational cohort study. <i>BMJ Open</i> , 2021, 11, e042355.	0.8	1
122	Surgical revision of candy cane after Roux-en-Y gastric bypass (RYGB). <i>Endocrine Abstracts</i> , 0, , .	0.0	1
123	SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	1
124	Adrenal Vein Sampling: Radiation Dose Reduction on New Angiography Platform. <i>The Arab Journal of Interventional Radiology</i> , 2020, 4, 102-106.	0.1	1
125	A case of severe hyponatraemia. <i>BMJ: British Medical Journal</i> , 2008, 337, a2377-a2377.	2.4	0
126	2308-PUB: Liraglutide 3 mg for Weight Loss in a Real-World Setting: Clinical Outcomes after 56 Weeks. <i>Diabetes</i> , 2019, 68, 2308-PUB.	0.3	0

#	ARTICLE	IF	CITATIONS
127	390-P: Changes in Glycaemic Variability after RYGB: A One-Year Prospective Study with Comparison to Patients with Post-bariatric Hypoglycaemia. <i>Diabetes</i> , 2019, 68, 390-P.	0.3	0
128	1798-P: Chronic Administration of a Long-Acting Glucagon Analogue Results in Enhanced Insulin Secretory Activity in a Directly-Observed Murine Model. <i>Diabetes</i> , 2020, 69, 1798-P.	0.3	0
129	Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia. <i>Lancet Diabetes and Endocrinology</i> , 2022, , .	5.5	0
130	Thyrotoxic periodic paralysis presenting as a broad complex tachycardia. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2021, 82, 1-3.	0.2	0